Equities

Glycorex Transplantation AB (publ)

0EMN:LSE

Glycorex Transplantation AB (publ)

Actions
  • Price (SEK)0.00
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change--
  • Beta--
Data delayed at least 20 minutes, as of Dec 30 1899.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Glycorex Transplantation publ AB is a Sweden-based medical device company engaged in the research, development, production and sales of medical devices within the field of organ transplantation. The Company's main product, Glycosorb-ABO, facilitates organ transplantation between different blood types. Additionally, the Company has developed complementary product variants, such as Glycosorb-ABO A/B-kolonn, designed for different patient categories, and Glycosorb-Xeno, which can facilitate transplants between animals and humans. As of December 31, 2011, Glycosorb-ABO was used in 103 transplantation centers in 22 countries. As of December 31, 2011, the Company had four wholly owned subsidiaries, namely Glycoprobe AB, Glycorex Transplantation, Glycorex UMC AB and Glycorex UBP AB.

  • Revenue in SEK (TTM)31.00m
  • Net income in SEK-29.54m
  • Incorporated1995
  • Employees15.00
  • Location
    Glycorex Transplantation AB (publ)Scheelevagen 27LUND 223 63SwedenSWE
  • Phone+46 462865230
  • Fax+46 462865239
  • Websitehttps://glycorex.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.